Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease.

Advanced Search

Liping Huang, Cheryl L McDade, Johnna E Perdrizet, Michele R Wilson, Sophie A Warren, Susan Nzenze, Renilla Sewdas

Author Information

Liping Huang: Pfizer Inc., 235 East 42nd Street, New York, NY, 10017, USA. liping.huang@pfizer.com. ORCID
Cheryl L McDade: RTI Health Solutions, PO Box 12194, Research Triangle Park, NC, USA.
Johnna E Perdrizet: Pfizer Inc., 235 East 42nd Street, New York, NY, 10017, USA.
Michele R Wilson: RTI Health Solutions, PO Box 12194, Research Triangle Park, NC, USA.
Sophie A Warren: Pfizer Inc., 235 East 42nd Street, New York, NY, 10017, USA.
Susan Nzenze: School of Public Health, University of the Witwatersrand, ZAF, Witwatersrand, USA.
Renilla Sewdas: Health and Value, Pfizer Laboratories (Pty) Ltd, ZAF, 500 Arcola Road, Collegeville, PA, 19460, USA.

PMID: 36774428 DOI: 10.1007/s40121-023-00767-4

INTRODUCTION: Pneumococcal disease, which presents a substantial health and economic burden, is prevented through pneumococcal vaccination programs. We assessed the impact of switching from a 13-valent-based (PCV13) to lower 10-valent-based (PCV10-GlaxoSmithKline [GSK] or PCV10-Serum Institute of India [SII]) or higher-valent (PCV15 or PCV20) vaccination programs in South Africa.
METHODS: A previously published decision-analytic model was adapted to a South African setting. Historical invasive pneumococcal disease (IPD) incidence data were used to project IPD incidence over time for each vaccination program on the basis of serotype coverage. Historical incidence (IPD, pneumonia, otitis media), mortality, costs, and utilities were obtained from the published literature. Cases of disease, direct medical costs (i.e., vaccination, IPD, pneumonia, and otitis media costs) (in 2022 South African rands), life-years, quality-adjusted life-years (QALY), and incremental cost per QALY were estimated over a 5- and 10-year horizon for PCV13 and the PCV10 vaccines. Additionally, a public health impact analysis was conducted comparing PCV13, PCV15, and PCV20.
RESULTS: Continuing use of PCV13 would substantially reduce disease incidence over time compared with switching to either of the PCV10 lower-valent vaccines. Cases of IPD were reduced by 4.22% and 34.70% when PCV13 was compared to PCV10-GSK and PCV10-SII, respectively. PCV13 was also found to be cost saving over 5- and 10-year time horizons compared with PCV10-SII and to be cost-effective over a 5-year time horizon and cost-saving over a 10-year time horizon compared with PCV10-GSK. PCV20 was consistently estimated to prevent more cases than the PCV10 vaccines, PCV13, or PCV15.
CONCLUSIONS: Switching from a higher-valent to a lower-valent vaccine may lead to disease incidence re-emergence caused by previously covered serotypes. Maintaining PCV13 was estimated to improve public health further by averting additional pneumococcal disease cases and saving more lives and also to reduce total costs in most scenarios. Higher-valent PCVs can achieve the greatest public health impact in the pediatric vaccination program in South Africa.

PCV PCV13 PCV20 Pneumococcal disease Vaccine

World Health Organization. Pneumococcal disease: the leading vaccine-preventable cause of death in children under five. 16 November 2016. https://www.gavi.org/pneumococcal-disease-leading-vaccine-preventable-cause-death-children-under-five . Accessed 24 August 2021.
Obaro S. Seven-valent pneumococcal conjugate vaccines for developing countries. Expert Rev Vacc. 2009;8(8):1051–61. https://doi.org/10.1586/erv.09.66 . [DOI: 10.1586/erv.09.66]
von Gottberg A, Cohen C, de Gouveia L, et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003–2008. Vaccine. 2013;31(38):4200–8. [DOI: 10.1016/j.vaccine.2013.04.077]
von Gottberg A, De Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014;371(20):1889–99. [DOI: 10.1056/NEJMoa1401914]
Yun J, Kleynhans J, Moyes J, et al. Epidemiology of respiratory pathogens from the influenza-like illness and pneumonia surveillance programmes, South Africa. 2019. https://www.nicd.ac.za/wp-content/uploads/2020/10/EPIDEMIOLOGY-OF-RESPIRATORY-PATHOGENS-FROM-THE-INFLUENZA-LIKE-ILLNESS-AND-PNEUMONIA-SURVEILLANCE-PROGRAMMES-SOUTH-AFRICA-2019.pdf . Accessed 17 August 2022.
Wasserman M, Palacios MG, Grajales AG, et al. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2019;15(3):560–9. https://doi.org/10.1080/21645515.2018.1516491 . [DOI: 10.1080/21645515.2018.1516491]
Wasserman M, Wilson M, Breton M, Peloquin F, McDade C, Farkouh R. Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to a lower-valent (PCV10) vaccine in Canada. Presented at the 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; 23–27 May 2017. Madrid, Spain.
Wasserman M, Wilson M, McDade C, et al. Estimating the clinical and economic impact of maintaining use of 13-valent pneumococcal conjugate vaccine (PCV13) in Mexico. Presented at the IDWeek 2017; 4–8 October 2017. San Diego, CA, USA.
Perdrizet J, Santana CFS, Senna T, et al. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants. Hum Vaccin Immunother. 2021;17(4):1162–72. https://doi.org/10.1080/21645515.2020.1809266 . [DOI: 10.1080/21645515.2020.1809266]
Pugh S, Wasserman M, Moffatt M, et al. Estimating the impact of switching from a lower to higher valent pneumococcal conjugate vaccine in Colombia, Finland, and the Netherlands: a cost-effectiveness analysis. Infect Dis Ther. 2020;9(2):305–24. https://doi.org/10.1007/s40121-020-00287-5 . [DOI: 10.1007/s40121-020-00287-5]
Wasserman MD, Sings HL, Wilson MR, et al. Re-analysis of modeling a switch from a 13-valent to 10-valent pneumococcal conjugate vaccine in Canada: leveraging real-world experience from Belgium. Infect Dis Ther. 2019;8(1):1–3. https://doi.org/10.1007/s40121-018-0222-1 . [DOI: 10.1007/s40121-018-0222-1]
Wilson M, Wasserman M, Breton M, et al. Potential clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Quebec. Presented at the Canadian Immunization Conference; 6–8 December 2016. Ottawa, Ontario, Canada.
Wilson M, Wasserman M, Jadavi T, et al. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018;7(3):353–71. https://doi.org/10.1007/s40121-018-0206-1 . [DOI: 10.1007/s40121-018-0206-1]
Perdrizet J, Horn EK, Nua W, et al. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) versus lower-valent alternatives in filipino infants. Infect Dis Ther. 2021;10(4):2625–42. https://doi.org/10.1007/s40121-021-00538-z . [DOI: 10.1007/s40121-021-00538-z]
Wilson MR, McDade CL, Perdrizet JE, Mignon A, Farkouh RA, Wasserman MD. Validation of a novel forecasting method for estimating the impact of switching pneumococcal conjugate programs: evidence from Belgium. Infect Dis Ther. 2021;10(3):1765–78. https://doi.org/10.1007/s40121-021-00485-9 . [DOI: 10.1007/s40121-021-00485-9]
Statistics South Africa. Mid-year population estimates 2018. 23 July 2018. Report No. P0302. https://www.statssa.gov.za/publications/P0302/P03022018.pdf . Accessed 10 August 2022.
National Institute for Communicable Diseases. National Health Laboratory Service. GERMS-SA Annual Report 2019. http://www.nicd.ac.za/index.php/publications/germs-annual-reports/ . Accessed 10 August 2022.
Tempia S, Moyes J, Cohen AL, et al. The national burden of influenza-like illness and severe respiratory illness overall and associated with nine respiratory viruses in South Africa, 2013–2015. Influenza Other Respir Viruses. 2022;16(3):438–51. [DOI: 10.1111/irv.12949]
Moore DP. University of the Witwatersrand, Johannesburg thesis 'Epidemiology of childhood pneumonia in the era of antiretroviral therapy and bacterial conjugate vaccines'. 2018.
Ministerio de Sanidad. Base de Datos Clínicos de Atención Primaria (BDCAP). Consulta Interativa del SNS. 2020. http://www.mscbs.es/ . Accessed 14 October 2022.
Biagio-de Jager L, Swanepoel DW, Laurent C, Lundberg T. Paediatric otitis media at a primary healthcare clinic in South Africa. S Afr Med J. 2014;104(6):431–5. [DOI: 10.7196/SAMJ.7534]
Walaza S, Buys A, Cohen C, Treurnicht F, Hellferscee O, Mcanerney J. Epidemiology of respiratory pathogens from influenza-like illness and pneumonia surveillance programmes. Natl Inst Commun Dis Bull. 2017;16:36–60.
Madhi SA, Govender N, Dayal K, et al. Bacterial and respiratory viral interactions in the etiology of acute otitis media in HIV-infected and HIV-uninfected South African children. Pediatr Infect Dis J. 2015;34(7):753. [DOI: 10.1097/INF.0000000000000733]
Statistics South Africa. Mortality and causes of death in South Africa: findings from death notification 2018. 15 June 2021. Report No. P0309.3. https://www.who.int/data/gho/data/countries/country-details/GHO/south-africa?countryProfileId=e5bf5e3c-86a3-421f-89cc-18d787c36968 . Accessed 22 August 2022.
Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–14. https://doi.org/10.1016/j.vaccine.2004.05.003 . [DOI: 10.1016/j.vaccine.2004.05.003]
Pan American Health Organization. PAHO revolving fund vaccine prices for 2022. 2022. https://www.paho.org/en/documents/paho-revolving-fund-vaccine-prices-2022 . Accessed 7 September 2022.
Department of Health. Medicines and Related Substances Act (101/1965) Regulations relating to a transparent pricing system for medicines and scheduled substances: Publication of guidelines for pharmacoeconomic submissions. Pretoria: Government Gazette. 2013.
Pfizer. Direct medical costs in South Africa. Key opinion leader input. Data on file. 2013.
Statistics South Africa (stats sa) Republic of South Africa. Consumer price index. 2022. https://www.statssa.gov.za/ . Accessed 7 September 2022.
Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539–45. https://doi.org/10.1016/j.jval.2010.10.029 . [DOI: 10.1016/j.jval.2010.10.029]
van Hoek AJ, Choi YH, Trotter C, Miller E, Jit M. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012;30(50):7205–13. https://doi.org/10.1016/j.vaccine.2012.10.017 . [DOI: 10.1016/j.vaccine.2012.10.017]
Bennett JE, Sumner W 2nd, Downs SM, Jaffe DM. Parents’ utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154(1):43–8. [PMID: 10632249]
Naucler P, Galanis I, Morfeldt E, Darenberg J, Örtqvist Å, Henriques-Normark B. Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations. Clin Infect Dis. 2017;65(11):1780–90. [DOI: 10.1093/cid/cix685]
Desmet S, Lagrou K, Wyndham-Thomas C, et al. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study. Lancet Infect Dis. 2021;21(1):127–36. https://doi.org/10.1016/s1473-3099(20)30173-0 . [DOI: 10.1016/s1473-3099(20)30173-0]
Clarke E, Bashorun A, Adigweme I, et al. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in the Gambia: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2021;21(6):834–46. https://doi.org/10.1016/s1473-3099(20)30735-0 . [DOI: 10.1016/s1473-3099(20)30735-0]
World Health Organization. WHO expert committee on biological standardization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines, Annex 3, TRS No 977. Replacement of WHO Technical Report Series, No. 927, Annex 2. 2013. https://www.who.int/publications/m/item/pneumococcal-conjugate-vaccines-annex3-trs-977 . Accessed 14 October 2022.
Madhi SA, Knoll MD. An affordable pneumococcal conjugate vaccine after 20 years. Lancet Infect Dis. 2021;21(6):751–3. https://doi.org/10.1016/s1473-3099(21)00002-5 . [DOI: 10.1016/s1473-3099(21)00002-5]
Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46. https://doi.org/10.1016/s1473-3099(14)70822-9 . [DOI: 10.1016/s1473-3099(14)70822-9]
Meiring S, Cohen C, Quan V, et al. HIV infection and the epidemiology of invasive pneumococcal disease (IPD) in South African adults and older children prior to the introduction of a pneumococcal conjugate vaccine (PCV). PLoS ONE. 2016;11(2):e0149104. https://doi.org/10.1371/journal.pone.0149104 . [DOI: 10.1371/journal.pone.0149104]
UNAIDS. South Africa HIV and AIDS Estimates in 2021. 2022. https://www.unaids.org/en/regionscountries/countries/southafrica . Accessed 7 September 2022.
Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J. 2000;19(12):1141–7. https://doi.org/10.1097/00006454-200012000-00004 . [DOI: 10.1097/00006454-200012000-00004]
Nunes MC, von Gottberg A, de Gouveia L, et al. Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program. PLoS ONE. 2011;6(11): e27929. [DOI: 10.1371/journal.pone.0027929]
Nzenze SA, von Gottberg A, Shiri T, et al. Temporal changes in pneumococcal colonization in HIV-infected and HIV-uninfected mother-child pairs following transitioning from 7-valent to 13-valent pneumococcal conjugate vaccine, Soweto. South Africa J Infect Dis. 2015;212(7):1082–92. https://doi.org/10.1093/infdis/jiv167 . [DOI: 10.1093/infdis/jiv167]
Feldman C, Dlamini SK, Madhi SA, et al. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults. PLoS ONE. 2020;15(1):e0227945. [DOI: 10.1371/journal.pone.0227945]
Spanish Ministry of Health. Consulta Interativa del SNS (mscbs.es). Base de Datos Clínicos de Atención Primaria (BDCAP) 2022. https://pestadistico.inteligenciadegestion.sanidad.gob.es/publicoSNS/S/base-de-datos-de-clinicos-de-atencion-primaria-bdcap . Accessed 24 October 2022.

Journal Article

OpenLB
Open Library of Bioscience